Incyte Corp
Change company Symbol lookup
Select an option...
INCY Incyte Corp
BSQR Bsquare Corp
APYX Apyx Medical Corp
XPEV Xpeng Inc
STX Seagate Technology Holdings PLC
EL Estee Lauder Companies Inc
CHND China Media Inc
BWG BrandywineGLOBAL ? Global Income Opportunities Fund
LCAAU L Catterton Asia Acquisition Corp
GME GameStop Corp

Health Care : Biotechnology | Mid Cap Growth
Company profile

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.


Last Trade
0.53 (0.66%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
June 13, 2022
FDA Approves Lilly and Incyte's OLUMIANT(R) (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT(R) (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe...(PR Newswire)

Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi(R) (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47

Pfizer Inc. (NASDAQ:PFE), MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ:MOR), and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration and supply agreement to investigate the immunotherapeutic...(BusinessWire)

May 26, 2022
Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June 9-17; virtual and in Vienna). (BusinessWire)

May 24, 2022
Incyte to Present at Upcoming Investor Conference

Incyte (Nasdaq:INCY) announced today that it will present at the 43rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022 at 8:00 a.m. (PDT) /11 a.m. (EDT) in Rancho Palos Verdes. (BusinessWire)

May 20, 2022
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT(R) (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT(R) (baricitinib) for the treatment...(PR Newswire)

May 11, 2022
FDA Approves Lilly and Incyte's OLUMIANT(R) (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

OLUMIANT is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S...(PR Newswire)

May 05, 2022
Incyte Announces European Commission Approval of Jakavi(R) (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Incyte (Nasdaq:INCY) today announced the European Commission (EC) has approved Jakavi(R) (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic GVHD who have inadequate response to corticosteroids or other systemic...(BusinessWire)

May 04, 2022
Incyte to Present at Upcoming Investor Conference

Incyte (Nasdaq:INCY) announced today that it will present at the 2022 RBC Capital Markets Healthcare Conference on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York. The presentation will be webcast live and can be accessed at

May 03, 2022
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs

--Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT Incyte (Nasdaq:INCY) today reports 2022 first quarter financial results, and provides a status update on the Company's clinical development portfolio. (BusinessWire)

April 28, 2022
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan

Incyte (NASDAQ:INCY) and Maruho Co., Ltd. today announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of...(BusinessWire)

April 22, 2022
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta(R)) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has issued a positive opinion that recommends granting marketing authorization for capmatinib (Tabrecta(R))...(BusinessWire)

April 12, 2022
Incyte to Report First Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 3, 2022. The schedule for the press release and conference call/webcast is as follows: (BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.